Cited by 2,514Global Cancer Incidence and ScreeningBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology Studies

The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.

Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

Antoni, Sebastien, Ferlay, Jacques, Soerjomataram, Isabelle, Znaor, Ariana, Jemal, Ahmedin, Bray, Freddie·2017·European Urology

DOI 10.1016/j.eururo.2016.06.010

Open this paper in CoChat — free account

Abstract

Context Bladder cancer has become a common cancer globally, with an estimated 430 000 new cases diagnosed in 2012. Objective We examine the most recent global bladder cancer incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder cancer. Evidence acquisition Global bladder cancer incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). Evidence synthesis Bladder cancer ranks as the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries. Conclusions The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder cancer statistics geographically or over time. Patient summary The main risk factor for bladder cancer is tobacco smoking. The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking.

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2016.06.010

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Self-citation
Cancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485
The United Nations Development Programme
Oestreich, J. E. (2017) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780190637347.003.0003 · Cited by 4,875
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Babjuk, M. M., Andreas Böhle, E., Burger, M., Čapoun, O., Cohen, D. L., Compérat, É., Hernández, V., KAASINEN, E. S., Palou, J., Morgan Rouprêt, A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.041 · Cited by 2,240
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Burger, M., Catto, J. W. F., Dalbagni, G. M., Grossman, H. B., Herr, H. W., Karakiewicz, P. I., Kassouf, W., Kiemeney, L. A. L. M., Vecchia, C. L., Shariat, S. F., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.07.033 · Cited by 2,212
Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk
Steinmann, P., Keiser, J., Bos, R., Tanner, M., & Utzinger, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70521-7 · Cited by 2,146
Smoking prevalence and cigarette consumption in 187 countries, 1980-2012
Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R. C., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,271
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174

Flagged first, then by citations

Show all 55 references

3 of the 55 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Loader C. Smoothing: Local Regression Techniques Web site. http://hdl.handle.net/10419/22186.

Sorted by citations

Items 101–200 of 1,000

The dynamic roles of the bladder tumour microenvironment
Lee, Y., Lam, H., Rosser, C. J., Theodorescu, D., Parks, W. C., & Chan, K. S. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00608-y · Cited by 111
Quantitative Identification of Nonmuscle‐Invasive and Muscle‐Invasive Bladder Carcinomas: A Multiparametric MRI Radiomics Analysis
Xu, X., Zhang, X., Tian, Q., Wang, H. J., Cui, L., Li, S., Tang, X., Baojuan Li, A., Dolz, J., Ayed, I. B., et al. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26327 · Cited by 104
USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer
Man, X., Piao, C., Lin, X., Kong, C., Cui, X., & Jiang, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1262-4 · Cited by 102
RETRACTED ARTICLE: Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer
Singh, A. K., Praharaj, M., Lombardo, K. A., Yoshida, T., Matoso, A., Baras, A. S., Zhao, L., Srikrishna, G., Huang, J., Prasad, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28509-z · Cited by 106
Retracted
Bladder Cancer: New Insights into Its Molecular Pathology
Inamura, K. (2018) · Cancers · doi:10.3390/cancers10040100 · Cited by 109
Increased accuracy of a novel mRNA ‐based urine test for bladder cancer surveillance
Pichler, R., Fritz, J., Tulchiner, G. A., Klinglmair, G., Soleiman, A., Horninger, W., Klocker, H., & Heidegger, I. M. (2017) · British Journal of Urology · doi:10.1111/bju.14019 · Cited by 99
CircNR3C1 inhibits proliferation of bladder cancer cells by sponging miR-27a-3p and downregulating cyclin D1 expression
Zheng, F., Wang, M., Li, Y., Huang, C., Tao, D., Xie, F., Zhang, H., Sun, J., Zhang, C., Gu, C., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.06.018 · Cited by 98
Update on the guideline of guidelines: non‐muscle‐invasive bladder cancer
Taylor, J. I., Becher, E., & Steinberg, G. D. (2019) · British Journal of Urology · doi:10.1111/bju.14915 · Cited by 98
Fluorinated Polymer Mediated Transmucosal Peptide Delivery for Intravesical Instillation Therapy of Bladder Cancer
Li, G., Lei, Q., Wang, F., Deng, D., Wang, S., Tian, L., Shen, W., Cheng, Y., Liu, Z., & Wu, S. (2019) · Small · doi:10.1002/smll.201900936 · Cited by 97
Sodium butyrate inhibits migration and induces AMPK‐mTOR pathway‐dependent autophagy and ROS‐mediated apoptosis via the miR‐139‐5p/Bmi‐1 axis in human bladder cancer cells
Wang, F., Wu, H., Fan, M., Yu, R., Zhang, Y., Liu, J., Zhou, X., Cai, Y., Huang, S., Hu, Z., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902626r · Cited by 101
Overview of VI-RADS in Bladder Cancer
Pecoraro, M., Takeuchi, M., Vargas, H. A., Muglia, V. F., Cipollari, S., Catalano, C., & Panebianco, V. (2020) · American Journal of Roentgenology · doi:10.2214/ajr.20.22763 · Cited by 97
An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers
Mahé, M., Dufour, F., Neyret‐Kahn, H., Moreno-Vega, A. I., Béraud, C., Shi, M., Hamaidi, I., Sánchez‐Quiles, V., Krucker, C., Dorland‐Galliot, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708163 · Cited by 100
MiR-22 suppresses epithelial–mesenchymal transition in bladder cancer by inhibiting Snail and MAPK1/Slug/vimentin feedback loop
Xu, M., Li, J., Wang, X., Meng, S., Shen, J., Wang, S., Xu, X., Xie, B., Liu, B., & Xie, L. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0206-1 · Cited by 95
A Review of the Etiology and Epidemiology of Bladder Cancer: All You Need To Know
Halaseh, S. A., Halaseh, S., Alali, Y., Ashour, M., & Alharayzah, M. J. (2022) · Cureus · doi:10.7759/cureus.27330 · Cited by 96
Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations
Klaassen, Z. W. A., Kamat, A. M., Kassouf, W., Gontero, P., Villavicencio, H., Joaquim Bellmunt, B., van Rhijn, B. W. G., Hartmann, A., Catto, J. W. F., & Kulkarni, G. S. (2018) · European Urology · doi:10.1016/j.eururo.2018.06.024 · Cited by 94
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
Mollica, V., Rizzo, A., Montironi, R., Liang Cheng, C., Giunchi, F., Schiavina, R., Santoni, M., Fiorentino, M., Antonio Lopez-beltran, B., Brunocilla, E., et al. (2020) · Cancers · doi:10.3390/cancers12061449 · Cited by 94
Narrow Bandgap Schottky Heterojunction Sonosensitizer with High Electron–Hole Separation Boosted Sonodynamic Therapy in Bladder Cancer
Li, G., Wu, S., Liu, J., Wang, K., Chen, X. S., & Liu, H. (2024) · Advanced Materials · doi:10.1002/adma.202401252 · Cited by 97
Radiomics analysis of multiparametric MRI for the preoperative evaluation of pathological grade in bladder cancer tumors
Wang, H. J., Hu, D., Yao, H., Chen, M.-D., Li, S., Chen, H., Luo, J., Feng, Y., & Guo, Y. (2019) · European Radiology · doi:10.1007/s00330-019-06222-8 · Cited by 93
circGprc5a Promoted Bladder Oncogenesis and Metastasis through Gprc5a-Targeting Peptide
Gu, C., Zhou, N., Wang, Z., Li, G., Kou, Y., Yu, S., Feng, Y., Chen, L., Yang, J., & Tian, F. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.10.008 · Cited by 93
Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer
Khan, K., Quispe, C., Javed, Z., Iqbal, M. J., Sadia, H., Raza, S., Irshad, A., Salehi, B., Reiner, Ž., & Sharifi‐Rad, J. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01660-7 · Cited by 92
HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1/PKM2 pathway
Lv, J., Li, K., Yu, H., Han, J., Zhuang, J., Yu, R., Cheng, Y., Song, Q., Bai, K., Cao, Q., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02614-3 · Cited by 93
Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer
Nazari, A., Khorramdelazad, H., & Hassanshahi, G. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1187-x · Cited by 91
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology
Reis, H., Serrette, R., Posada, J., Lu, V., Chen, Y., Gopalan, A., Fine, S. W., Tickoo, S. K., Sirintrapun, S. J., Iyer, G., et al. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001264 · Cited by 90
Poly(amidoamine)-modified mesoporous silica nanoparticles as a mucoadhesive drug delivery system for potential bladder cancer therapy
Wang, B., Zhang, K., Wang, J., Zhao, R., Zhang, Q., & Kong, X. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.110832 · Cited by 90
Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer
Hu, B., Wang, Z., Zeng, H., Qi, Y., Chen, Y., Wang, T., Wang, J., Chang, Y., Bai, Q., Xia, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2254 · Cited by 93
Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study
Catto, J. W. F., Khetrapal, P., Ambler, G., Sarpong, R., Khan, M. S., Tan, M., Feber, A., Dixon, S., Goodwin, L., Williams, N. R., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020500 · Cited by 89
Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer
Miyamoto, D. T., Mouw, K. W., Feng, F. Y.-C., Shipley, W. U., & Efstathiou, J. A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30693-4 · Cited by 85
Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application
Makboul, M., Farghaly, S., & Abdelkawi, I. F. (2019) · British Journal of Radiology · doi:10.1259/bjr.20190401 · Cited by 87
Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma
Maimaiti, M., Sakamoto, S., Yamada, Y., Sugiura, M., Rii, J., Takeuchi, N., Imamura, Y., Furihata, T., Ando, K., Higuchi, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58136-x · Cited by 87
Androgen receptor‐regulated circFNTA activates KRAS signaling to promote bladder cancer invasion
Chen, J., Sun, Y., Ou, Z., Yeh, S., Huang, C., You, B., Tsai, Y., Sheu, T., Zu, X., & Chang, C. (2020) · EMBO Reports · doi:10.15252/embr.201948467 · Cited by 86
RETRACTED ARTICLE: Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1
Jia, Y., Ding, X., Zhou, L., Zhang, L., & Yang, X. (2020) · Oncogene · doi:10.1038/s41388-020-01486-7 · Cited by 87
Retracted
The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer
Nair, S. S., Weil, R., Dovey, Z. S., Davis, A., & Tewari, A. K. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.10.005 · Cited by 88
Molecular profiling in muscle‐invasive bladder cancer: more than the sum of its parts
Sjödahl, G., Jackson, C. L., Bartlett, J. M. S., Siemens, D. R., & Berman, D. M. (2019) · The Journal of Pathology · doi:10.1002/path.5230 · Cited by 90
Differences in trends in the use of robot‐assisted and open radical cystectomy and changes over time in peri‐operative outcomes among selected centres in North America and Europe: an international multicentre collaboration
Zamboni, S., Soria, F., Mathiéu, R., Xylinas, E. N., Abufaraj, M. M., D’Andrea, D., Tan, W. S., Kelly, J. D., Simone, G., Gallucci, M., et al. (2019) · British Journal of Urology · doi:10.1111/bju.14791 · Cited by 85
Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018
Lotan, Y., Bivalacqua, T. J., Downs, T. M., Huang, W. C. W., Jones, J. A., Kamat, A. M., Konety, B. R., Malmström, P., McKiernan, J., O’Donnell, M. A., et al. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0184-4 · Cited by 85
The Emerging Role of Epitranscriptomics in Cancer: Focus on Urological Tumors
Lobo, J., Barros‐Silva, D., Henrique, R., & Jerónimo, C. (2018) · Genes · doi:10.3390/genes9110552 · Cited by 84
Circular RNA circPICALM sponges miR-1265 to inhibit bladder cancer metastasis and influence FAK phosphorylation
Yan, D., Dong, W., He, Q., Yang, M., Huang, L., Kong, J., Qin, H., Lin, T., & Huang, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.074 · Cited by 86
Cancer‐Associated Fibroblast‐Induced Remodeling of Tumor Microenvironment in Recurrent Bladder Cancer
Liang, T., Tao, T., Wu, K., Liu, L., Xu, W., Zhou, D., Hu, F., Ding, Q., Huang, G., & Wu, S. (2023) · Advanced Science · doi:10.1002/advs.202303230 · Cited by 85
mRNA, microRNA and lncRNA as novel bladder tumor markers
Wieczorek, E., & Reszka, E. (2017) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.12.009 · Cited by 82
Noninvasive Detection of Bladder Cancer by Shallow-Depth Genome-Wide Bisulfite Sequencing of Urinary Cell-Free DNA for Methylation and Copy Number Profiling
Cheng, T. H. T., Jiang, P., Teoh, J. Y., Heung, M. M. S., Tam, J. C. W., Sun, X., Lee, W., Ni, M., Chan, R., Ng, C., et al. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.301341 · Cited by 82
Circular RNA DOCK1 promotes bladder carcinoma progression via modulating circDOCK1/hsa‐miR‐132‐3p/Sox5 signalling pathway
Liu, P., Li, X., Guo, X., Chen, J., Li, C., Chen, M., Liu, L., Zhang, X., & Zu, X. (2019) · Cell Proliferation · doi:10.1111/cpr.12614 · Cited by 83
CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer
Chen, X., Xu, R., He, D., Zhang, Y., Chen, H., Zhu, Y., Cheng, Y., Liu, R., Zhu, R., Gong, L., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02019-6 · Cited by 81
Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance
Ashrafizadeh, M., Dai, J., Torabian, P., Nabavi, N., Aref, A. R., Aljabali, A. A. A., Tambuwala, M. M., & Zhu, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05236-w · Cited by 83
Multiregion segmentation of bladder cancer structures in MRI with progressive dilated convolutional networks
Dolz, J., Xu, X., Rony, J., Yuan, J., Liu, Y., Granger, É., Desrosiers, C., Zhang, X., Ayed, I. B., & Lu, H. (2018) · Medical Physics · doi:10.1002/mp.13240 · Cited by 81
The biogenesis and biological functions of circular RNAs and their molecular diagnostic values in cancers
Zhang, H., Shen, Y., Li, Z., Ruan, Y., Li, T., Xiao, B., & Sun, W. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23049 · Cited by 80
Recent advances and possibilities for the use of plant phenolic compounds to manage ageing-related diseases
Arruda, H. S., Neri-Numa, I. A., Kido, L. A., Maróstica, M. R., & Pastore, G. M. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104203 · Cited by 85
MET/SMAD3/SNAIL circuit mediated by miR-323a-3p is involved in regulating epithelial–mesenchymal transition progression in bladder cancer
Li, J., Xu, X., Meng, S., Liang, Z. C., Wang, X., Xu, M., Wang, S., Li, S., Zhu, Y., Xie, B., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.331 · Cited by 80
Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases
Wang, G., Xiao, L., Zhang, M., Kamat, A. M., Siefker-Radtke, A. O., Dinney, C. P., Czerniak, B. A., & Guo, C. C. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.05.005 · Cited by 79
lncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasion
Zhang, C., Wang, W., Lin, J., Xiao, J., & Tian, Y. (2019) · International braz j urol · doi:10.1590/s1677-5538.ibju.2018.0450 · Cited by 79
The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies
Zhang, Z., Fan, W., Deng, Q., Tang, S., Wang, P., Xu, P., Wang, J., & Yu, M. (2017) · Oncotarget · doi:10.18632/oncotarget.18521 · Cited by 79
NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation
Xiong, M., Chen, L., Zhou, L., Ding, Y., Kazobinka, G., Chen, Z., & Hou, T. (2019) · Theranostics · doi:10.7150/thno.36030 · Cited by 77
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non–Muscle-Invasive Bladder Cancer
Joaquim Bellmunt, B., Kim, J., Reardon, B. M., Perera‐Bel, J., Orsola, A., Rodríguez‐Vida, A., Wankowicz, S. A. M., Bowden, M., Barletta, J. A., Moróte, J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0977 · Cited by 77
Curcumin inhibits urothelial tumor development by suppressing IGF2 and IGF2-mediated PI3K/AKT/mTOR signaling pathway
Tian, B., Zhao, Y., Liang, T., Ye, X., Li, Z., Yan, D., Fu, Q., & Li, Y. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1306535 · Cited by 76
Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer
Avogbe, P. H., Manel, A., Vian, E., Durand, G., Forey, N., Voegele, C., Zvereva, M. I., Hosen, M. I., Meziani, S., Tilly, B. D., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.004 · Cited by 76
An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle‐invasive bladder cancer (MIBC)
Jiang, W., Zhu, D., Wang, C., & Zhu, Y. (2020) · Cancer Medicine · doi:10.1002/cam4.2942 · Cited by 76
Role of immunotherapy in bladder cancer: past, present and future
Butt, S.-U.-R., & Malik, L. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3518-7 · Cited by 74
MiR-454-3p and miR-374b-5p suppress migration and invasion of bladder cancer cells through targetting ZEB2
Wang, S., Zhang, G., Zheng, W., Qin, X. Y., Wei, D., Zheng, Y., & Yuan, J. (2018) · Bioscience Reports · doi:10.1042/bsr20181436 · Cited by 74
Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients
Hamid, A. R. A. H., Ridwan, F. R., Parikesit, D., Widia, F., Mochtar, C. A., & Umbas, R. (2020) · BMC Urology · doi:10.1186/s12894-020-00733-z · Cited by 75
Advances in Management of Bladder Cancer—The Role of Photodynamic Therapy
Kubrak, T. P., Karakuła, M., Czop, M., Kawczyk‐Krupka, A., & Aebisher, D. (2022) · Molecules · doi:10.3390/molecules27030731 · Cited by 74
EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway
Luo, K.-W., Lung, W.-Y., Chun-Xie, Luo, X., & Huang, W. (2018) · Oncotarget · doi:10.18632/oncotarget.24301 · Cited by 74
Health-related quality of life after treatment for bladder cancer in England
Mason, S. J., Downing, A., Wright, P., Hounsome, L. S., Bottomley, S. E., Corner, J. L., Richards, M. A., Catto, J. W. F., & Glaser, A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0084-z · Cited by 74
Inhibition of stearoyl CoA desaturase‐1 activity suppresses tumour progression and improves prognosis in human bladder cancer
Piao, C., Cui, X., Zhan, B., Li, J., Li, Z., Li, Z., Liu, X., Bi, J., Zhang, Z., & Kong, C. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14114 · Cited by 74
Long noncoding RNA UCA1 targets miR-582-5p and contributes to the progression and drug resistance of bladder cancer cells through ATG7-mediated autophagy inhibition
Wu, J., Li, W., Ning, J., Yu, W., Rao, T., & Cheng, F. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s183940 · Cited by 73
Retracted
The Cost to Medicare of Bladder Cancer Care.
Sloan, F., Yashkin, A., Akushevich, I., & Inman, B. (2020) · European Urology Oncology · doi:10.1016/j.euo.2019.01.015 · Cited by 75
Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
de Jong, J. J., Hendricksen, K., Rosier, M., Mostafid, H. A., & Boormans, J. L. (2018) · Bladder Cancer · doi:10.3233/blc-180191 · Cited by 71
Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for Bladder Cancer
Abugomaa, A., Elbadawy, M., Yamawaki, H., Usui, T., & Sasaki, K. (2020) · Cells · doi:10.3390/cells9010235 · Cited by 75
Cancer survival in adult patients in Spain. Results from nine population-based cancer registries
the REDECAN Working Group, Chirlaque, M., Salmerón, D., Galcerán, J., Ameijide, A., Mateos, A., Torrella, A., Jiménez, R., Larrañaga, N., Marcos‐Gragera, R., et al. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1710-6 · Cited by 73
Bladder cancer survival: Women better off in the long run
Kulle, B., Grimsrud, T. K., & Haug, E. S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.001 · Cited by 71
Biological roles of RNA m7G modification and its implications in cancer
Zhang, X., Zhu, W., Shen, S., Shen, J., & Chen, X.-D. (2023) · Biology Direct · doi:10.1186/s13062-023-00414-5 · Cited by 72
Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells
Cao, Y., Sun, J., Li, M., Dong, Y., Zhang, Y.-H., Yan, J., Huang, R., & Yan, X. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0205-5 · Cited by 70
Identifying non-muscle-invasive and muscle-invasive bladder cancer based on blood serum surface-enhanced Raman spectroscopy
Chen, S., Zhu, S., Cui, X., Xu, W., Kong, C., Zhang, Z., & Qian, W. (2019) · Biomedical Optics Express · doi:10.1364/boe.10.003533 · Cited by 70
The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder
Calvete, J., Larrinaga, G., Errarte, P., Martín, A. M., Dotor, A. M., Esquinas, C., Nunes‐Xavier, C. E., Pulido, R., Lopez, J. I., & Angulo, J. C. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.07.002 · Cited by 70
Cancer mortality in Europe in 2015 and an overview of trends since 1990
Bertuccio, P., Alicandro, G., Malvezzi, M., Carioli, G., Boffetta, P., Levi, F., Vecchia, C. L., & Negri, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz179 · Cited by 70
Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer
Monteiro‐Reis, S., Lobo, J., Henrique, R., & Jerónimo, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020297 · Cited by 67
Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis
Al‐Husseini, M. J., Kunbaz, A., Saad, A. M., Santos, J. V., Salahia, S. I., Iqbal, M., & Alahdab, F. (2019) · BMC Cancer · doi:10.1186/s12885-019-5267-3 · Cited by 69
The future burden of cancer in Canada: Long-term cancer incidence projections 2013–2042
Poirier, A. E., Ruan, Y., Walter, S. D., Franco, E. L., Villeneuve, P. J., King, W. D., Volesky, K. D., O'Sullivan, D. E., Friedenreich, C. M., & Brenner, D. R. (2019) · Cancer Epidemiology · doi:10.1016/j.canep.2019.02.011 · Cited by 69
Regulatory Components of Oxidative Stress and Inflammation and Their Complex Interplay in Carcinogenesis
Dharshini, L. C. P., Rasmi, R. R., Kathirvelan, C., Kumar, K. M., Saradhadevi, K. M., & Sakthivel, K. M. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-04266-z · Cited by 77
Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis
Li, X., Gu, L., Chen, Y., Chong, Y., Wang, X., Guo, P., & He, D. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1991591 · Cited by 68
In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival
Breyer, J., Wirtz, R. M., Otto, W., Erben, P., KRIEGMAIR, M. C., Stoehr, R., Eckstein, M., Eidt, S., Denzinger, S., Burger, M., et al. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2064-8 · Cited by 68
Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
Sakaguchi, T., Yoshino, H., Yonemori, M., Miyamoto, K., Sugita, S., Matsushita, R., Itesako, T., Tatarano, S., Nakagawa, M., & Enokida, H. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.43 · Cited by 68
Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer
Girard, A., Rouanne, M., Taconet, S., Radulescu, C., Neuzillet, Y., Girma, A., Bèaufrere, A., Lebrét, T., Stanc, E. L., & Grellier, J.-F. (2019) · European Radiology · doi:10.1007/s00330-018-5959-0 · Cited by 68
Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles
de Oliveira, M. C., Caires, H. R., Oliveira, M. J., Fraga, A. M., Vasconcelos, M. H., & Ribeiro, R. J. T. (2020) · Cancers · doi:10.3390/cancers12061400 · Cited by 69
Tumor Cell Dissociation Removes Malignant Bladder Tumors
Bao, Q., Hu, P., Ren, W., Guo, Y., & Shi, J. (2020) · Chem · doi:10.1016/j.chempr.2020.06.013 · Cited by 68
Deep learning-based classification of blue light cystoscopy imaging during transurethral resection of bladder tumors
Ali, N., Bolenz, C., Todenhöfer, T., Stenzel, A., Deetmar, P., Kriegmair, M., Knoll, T., Porubský, Š., Hartmann, A., Popp, J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91081-x · Cited by 67
MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer
Wang, J., Liu, B., Zhou, L., & Huang, Y.-X. (2019) · Cancer Biomarkers · doi:10.3233/cbm-182000 · Cited by 66
Predictive biomarkers for drug response in bladder cancer
Yoshida, T., Kates, M. R., Fujita, K., Bivalacqua, T. J., & McConkey, D. J. (2019) · International Journal of Urology · doi:10.1111/iju.14082 · Cited by 65
PTEN: What we know of the function and regulation of this onco-suppressor factor in bladder cancer?
Ashrafizadeh, M., Zarrabi, A., Samarghandian, S., & Najafi, M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173226 · Cited by 66
Causal associations between gut microbiota and urological tumors: a two-sample mendelian randomization study
Mingdong, W., Gao, X., Yongjun, Q., Mingshuai, W., & Hao, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-11383-3 · Cited by 69
Targeted O‐glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced‐stage bladder tumours
Cotton, S., Azevedo, R., Gaiteiro, C., Ferreira, D., Lima, L., Peixoto, A., Fernandes, E., Neves, M., Neves, D., Amaro, T., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12035 · Cited by 66
CD 169‐positive sinus macrophages in the lymph nodes determine bladder cancer prognosis
Asano, T., Ohnishi, K., Shiota, T., Motoshima, T., Sugiyama, Y., Yatsuda, J., Kamba, T., Ishizaka, K., & Komohara, Y. (2018) · Cancer Science · doi:10.1111/cas.13565 · Cited by 66
Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer
Fukushima, H., Takemura, K. N., Suzuki, H., & Koga, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102999 · Cited by 65
CT-based radiomics to predict the pathological grade of bladder cancer
Zhang, G., Xu, L., Zhao, L., Mao, L., Li, X., Jin, Z., & Sun, H. (2020) · European Radiology · doi:10.1007/s00330-020-06893-8 · Cited by 64
Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
Roviello, G., Catalano, M., Santi, R., Palmieri, V. E., Vannini, G., Galli, I. C., Buttitta, E., Villari, D., Rossi, V., & Nesi, G. (2021) · Cancers · doi:10.3390/cancers13174411 · Cited by 66
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer
Chevuru, P. T., McElree, I. M., Mott, S. L., Steinberg, R. L., O’Donnell, M. A., & Packiam, V. T. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.10.030 · Cited by 64
Long-term Outcomes from Re-resection for High-risk Non–muscle-invasive Bladder Cancer: A Potential to Rationalize Use
Gordon, P. C., Thomas, F., Noon, A. P., Rosario, D. J., & Catto, J. W. F. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.10.004 · Cited by 64
An inverse association between the Mediterranean diet and bladder cancer risk: a pooled analysis of 13 cohort studies
Witlox, W. J. A., van Osch, F., Brinkman, M. T., Jochems, S. H. J., Goossens, M. E., Weiderpass, E., White, E., van den Brandt, P. A., Giles, G. G., Milne, R. L., et al. (2019) · European Journal of Nutrition · doi:10.1007/s00394-019-01907-8 · Cited by 67
RNA-Binding Protein ZFP36L1 Suppresses Hypoxia and Cell-Cycle Signaling
Loh, X.-Y., Sun, Q., Ding, L., Mayakonda, A., Venkatachalam, N., Yeo, M.-S., Silva, T. C., Xiao, J.-F., Doan, N., SAID, J. W., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2796 · Cited by 63
A nomogram combining long non-coding RNA expression profiles and clinical factors predicts survival in patients with bladder cancer
Wang, Y., Du, L., Yang, X., Li, J., Li, P., Zhao, Y., Duan, W., Chen, Y., Wang, Y., Mao, H., et al. (2020) · Aging · doi:10.18632/aging.102782 · Cited by 63
Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review
Mori, K., Miura, N., Babjuk, M., Karakiewicz, P. I., Mostafaei, H., Laukhtina, E., Quhal, F., Motlagh, R. S., Pradère, B., Kimura, S., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.06.013 · Cited by 63
Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer
Wang, J., Shen, C., Dong, D., Zhong, X., Wang, Y., & Yang, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107146 · Cited by 63

Authors: Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F.
Affiliations: Centre international de recherche sur le cancer (FR)
American Cancer Society (US)
Corresponding author: Bray, Freddie
ORCID: Ferlay, Jacques
Soerjomataram, Isabelle
Znaor, Ariana
Jemal, Ahmedin
Bray, Freddie
Venue: European Urology
Publisher: Elsevier BV
Published: 2017-01
Volume: 71
Issue: 1
Pages: 96-108
ISSN: 0302-2838 (ISSN-L)
DOI: 10.1016/j.eururo.2016.06.010
OpenAlex: W2473162054
Cited by: 2,514
References: 55
Citations by year: 2026: 79 · 2025: 165 · 2024: 248 · 2023: 244 · 2022: 314 · 2021: 414 · 2020: 400 · 2019: 306 · 2018: 225 · 2017: 102
FWCI: 21.58
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: European Urology (publishedVersion)
PubMed (publishedVersion)
Funders: World Health Organization
Topics: Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
Keywords: bladder cancer, cancer incidence, cancer mortality, incidence trends, sex differences, smoking, Schistosoma haematobium, etiology, global cancer statistics
MeSH terms: Urinary Bladder Neoplasms, Female, Humans, Male, Registries, Risk Factors, Smoking, Global Health, Incidence, Internationality

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks